|
Re: 3 point MACE in Phase 3 should be 10% percent lower than 4 point MACE in Phase 2's
|
3
|
Resverlogix Corp.
|
Nov 06, 2018 11:19AM
|
|
Re: Presentation
|
3
|
Resverlogix Corp.
|
Oct 23, 2020 10:03AM
|
|
Zenith Announces Voting Results from the 2020 Annual and Special Meeting of Shareholders
|
3
|
Zenith Epigenetics
|
Dec 23, 2020 04:29PM
|
|
Re: Showcase Presentations
|
3
|
Resverlogix Corp.
|
Jan 17, 2017 06:43AM
|
|
Re: what of zenith and all our shars we have from that origional invetment?
|
3
|
Resverlogix Corp.
|
Jun 24, 2018 06:24PM
|
|
Re: Holding steady
|
3
|
Resverlogix Corp.
|
Dec 22, 2018 09:37PM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex
|
3
|
Resverlogix Corp.
|
Dec 04, 2018 01:35PM
|
|
Re: Bear
|
3
|
Zenith Epigenetics
|
Oct 09, 2020 05:23PM
|
|
Re: Biogen/Eisai Scrap Aducanumab
|
3
|
Resverlogix Corp.
|
Mar 24, 2019 05:28PM
|
|
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
|
3
|
Resverlogix Corp.
|
Jul 08, 2019 12:56PM
|
|
Re: breaking news...Apple forms secret team to address Diabetes?
|
3
|
Resverlogix Corp.
|
Apr 13, 2017 10:23AM
|
|
Re: Will Phase 2a Renal trial start tomorrow?
|
3
|
Resverlogix Corp.
|
Jun 15, 2017 04:49PM
|
|
Re: AACR 2019
|
3
|
Zenith Epigenetics
|
Feb 28, 2019 10:18AM
|
|
More confirmation of BETonMACE commencing/enrolling in Fall 2015
|
3
|
Resverlogix Corp.
|
Jul 28, 2015 09:38PM
|
|
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
|
3
|
Zenith Epigenetics
|
Jun 27, 2019 08:36AM
|
|
Re: Zenith AGM Dec 15
|
3
|
Zenith Epigenetics
|
Oct 18, 2016 09:25AM
|
|
Re: Bromodomain and extraterminal domain (BET) inhibitors in clinical development
|
3
|
Resverlogix Corp.
|
Apr 16, 2019 08:38PM
|
|
Re: AACR 2018
|
3
|
Zenith Epigenetics
|
Feb 28, 2018 05:57PM
|
|
Re: We Need An Update
|
3
|
Resverlogix Corp.
|
Jul 17, 2015 02:58PM
|
|
Re: A fair and optimistic write up on BETonMACE
|
3
|
Resverlogix Corp.
|
Nov 25, 2019 12:25PM
|
